Research & Regulatory News

REDEFINE 4: The Head-to-Head Novo Nordisk Lost

UKPWritten and published by UK Peptides2 min readUpdated 3 cited sources

The short answer

REDEFINE 4, registered as NCT06131437, randomised 809 adults to CagriSema or tirzepatide 15 mg over 84 weeks. Its primary objective was to confirm non-inferiority of CagriSema, and that objective was not met, 23.0% against 25.5% on the efficacy estimand.

Key facts

Registration
NCT06131437
Sponsor
Novo Nordisk A/S
Phase
3
Enrolment
809
Design
Randomised, masking none (open-label)
Arms
CagriSema 2.4/2.4 mg vs tirzepatide 15 mg
Started
27 November 2023
Completed
9 January 2026
Efficacy estimand
23.0% vs 25.5%
Treatment-policy estimand
20.2% vs 23.6%
Primary endpoint
Non-inferiority (not met)

What the registry says

The ClinicalTrials.gov record states the official title as an efficacy and safety study of cagrilintide 2.4 mg with semaglutide 2.4 mg once weekly compared to tirzepatide 15 mg. Phase 3, 809 participants, randomised, masking none. Started 27 November 2023, primary completion 8 December 2025, completed 9 January 2026. The primary outcome is written as confirming non-inferiority of CagriSema versus tirzepatide on relative change in body weight.

What was reported

On the efficacy estimand (which asks what happens if everyone adheres) CagriSema reached 23.0% and tirzepatide 25.5%. On the treatment-policy estimand, which counts everyone regardless of adherence, the figures were 20.2% and 23.6%. The primary objective of demonstrating non-inferiority was not met.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

What that does and does not mean

It means non-inferiority was not demonstrated. It does not mean inferiority was demonstrated. Those are different findings, and coverage describing CagriSema as bested by or falling to its comparator collapses the distinction. It also does not mean CagriSema failed to work: 23.0% is a large weight reduction by any standard the field had before 2022.

The estimand gap is worth reading

Within this one trial, from the same participants, the two estimands differ by 2.8 points for CagriSema and 1.9 for tirzepatide. Nothing about the drugs changes between those numbers. Only how discontinuation is handled. A figure quoted without stating which estimand produced it cannot be compared with anything.

The design limitation

Masking none. Participants and investigators knew which drug was being given, and body weight is an outcome behaviour influences. Blinding two injectables with different devices and side-effect profiles is hard, so this is a practical constraint rather than an oversight, but it weakens the comparison and belongs beside the numbers.

Why running it at all was notable

Head-to-head trials against a strong comparator are risky, and this one produced a public result the sponsor did not want. Novo Nordisk ran it anyway, at a time when prescribers and payers increasingly expect direct evidence rather than cross-trial comparison.

What this has no bearing on

Research material. Tirzepatide is a licensed medicine; CagriSema is filed and unapproved. Both were administered in a registered trial under clinical supervision. Nothing supplied here is related to either, is an alternative to either, or is described by these results.

Frequently asked questions

Did CagriSema fail?

It did not meet its primary endpoint of non-inferiority. It still produced 23.0% weight reduction on the efficacy estimand, which is a large effect.

Why are two sets of numbers reported?

Two estimands. The efficacy estimand assumes adherence; the treatment-policy estimand counts everyone regardless. Same participants, different handling of discontinuation.

Was the trial blinded?

No. The registry lists allocation as randomised and masking as none.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More Research & Regulatory News articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.